# A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

> **NCT04771507** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jeanette Lundin** · enrollment: 50 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT04771507
- **Lead sponsor:** Jeanette Lundin
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-23
- **Primary completion:** 2023-04-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04771507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04771507, "A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04771507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*